Compare GKOS & GATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GKOS | GATX |
|---|---|---|
| Founded | 1998 | 1898 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Transportation Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 6.6B |
| IPO Year | 2015 | 1994 |
| Metric | GKOS | GATX |
|---|---|---|
| Price | $122.45 | $171.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 2 |
| Target Price | $126.92 | ★ $215.50 |
| AVG Volume (30 Days) | ★ 779.2K | 174.6K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 1.36% |
| EPS Growth | N/A | ★ 17.22 |
| EPS | N/A | ★ 2.35 |
| Revenue | $507,442,000.00 | ★ $1,740,400,000.00 |
| Revenue This Year | $23.32 | $42.21 |
| Revenue Next Year | $27.43 | $3.35 |
| P/E Ratio | ★ N/A | $73.52 |
| Revenue Growth | ★ 32.33 | 9.77 |
| 52 Week Low | $73.16 | $144.56 |
| 52 Week High | $148.11 | $205.56 |
| Indicator | GKOS | GATX |
|---|---|---|
| Relative Strength Index (RSI) | 40.86 | 33.30 |
| Support Level | $79.59 | $166.88 |
| Resistance Level | $123.09 | $175.83 |
| Average True Range (ATR) | 6.56 | 4.85 |
| MACD | -1.43 | -2.15 |
| Stochastic Oscillator | 5.60 | 9.51 |
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
GATX Corp leases transportation assets, including railcars, aircraft spare engines, and tank containers, to customers in North America, Europe, and India. The company's reportable business segments are: Rail North America, Rail International, Engine Leasing, and Other. The majority of its revenue is generated from the Rail North America segment, which is composed of the company's operations in the United States, Canada, and Mexico. This segment mainly provides railcars pursuant to full-service leases under which it maintains the railcars, pays ad valorem taxes and insurance, and provides other ancillary services.